Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

被引：0
|
作者：
Gurwitz, David [1 ]
Newman, William [2 ]
机构：
[1] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[2] Univ Manchester, Dept Med Genet, Manchester M13 9PL, Lancs, England
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2008年 / 100卷 / 18期
关键词：
D O I：
10.1093/jnci/djn269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [11] CYP2D6 and adjuvant tamoxifen: Impact on outcome in pre- but not postmenopausal breast cancer patients
    Margolin, S.
    Lindh, J.
    Thoren, L.
    Xie, H.
    Koukel, L.
    Dahl, M-L
    Eliasson, E.
    CANCER RESEARCH, 2012, 72
  • [12] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 176 - 180
  • [13] Endocrine Therapy: Translational Research on CYP2D6 Genetics for Tamoxifen Response in Breast Cancer
    Branch, H.
    Schroth, W.
    Bacchus, L.
    Simon, W.
    Eichelbaum, M.
    Schwab, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (12) : 1223 - 1224
  • [14] Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
    Wei, Xiaoxia
    Sun, Hong
    Zhuang, Jie
    Weng, Xiuhua
    Zheng, Bin
    Lin, Qiwang
    Zhang, Guifeng
    Cai, Jiaqin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (01) : 25 - 32
  • [15] Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
    Xiaoxia Wei
    Hong Sun
    Jie Zhuang
    Xiuhua Weng
    Bin Zheng
    Qiwang Lin
    Guifeng Zhang
    Jiaqin Cai
    Clinical Drug Investigation, 2020, 40 : 25 - 32
  • [16] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [17] The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population
    Lan, Bo
    Ma, Fei
    Zhai, Xiaoyu
    Li, Qiao
    Chen, Shanshan
    Wang, Jiayu
    Fan, Ying
    Luo, Yang
    Cai, Ruigang
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 184 - 189
  • [18] Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes
    Li, Xin
    Li, Zehao
    Li, Lin
    Liu, Tong
    Qian, Cheng
    Ren, Yanlv
    Li, Zhigao
    Chen, Kejin
    Ji, Dongchen
    Zhang, Ming
    Wang, Jinsong
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 134 - 142
  • [19] CYP2D6 Genotype Should Not Be Used for Deciding About Tamoxifen Therapy in Postmenopausal Breast Cancer
    Rae, James M.
    Regan, Meredith
    Leyland-Jones, Brian
    Hayes, Daniel F.
    Dowsett, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (21) : 2753 - 2755
  • [20] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    T. Ramón y Cajal
    A. Altés
    L. Paré
    E. del Rio
    C. Alonso
    A. Barnadas
    M. Baiget
    Breast Cancer Research and Treatment, 2010, 119 : 33 - 38
12345